NASDAQ - ACADIA Pharmaceuticals Inc.

График котировок ACADIA Pharmaceuticals Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 7.46
P/BV 5.24
EV/EBITDA -11.76
EBITDA -0.2309
Цена ао 20.6

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 7.46 1
P/BV 5.24 1
P/E 0
EV/EBITDA -11.76 10

Эффективность

Название Значение Оценка
ROA, % -18.66 1
ROE, % -42.47 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 10

Импульс роста

Название Значение Оценка
Рост прибыли, % 76.36 10
Рост цены акции, % 72.67 10
Рост дивидендов, % 0 0

Основные владельцы

Институционалы Объем Доля, %
Baker Bros Advisors LP 41904586 26.18
Fidelity Management & Research Company LLC 24539088 15.33
BlackRock Fund Advisors 9798933 6.12
Columbia Wanger Asset Management LLC 2385786 1.49
Palo Alto Investors, LLC 2301477 1.44
American Century Investment Management, Inc 2148383 1.34
Invesco Advisers, Inc. 1099570 0.69
Great Point Partners LLC 720502 0.45
International Biotechnology Trust PLC 486000 0.3
SV Life Sciences Managers LLP 486000 0.3
Fairmount Funds Management LLC 450317 0.28
AMG Funds LLC 305831 0.19
Principal Global Investors, LLC 179617 0.11
Security Investors, LLC 146288 0.09
Weatherbie Capital, LLC 56718 0.04
Riedweg & Hrovat AG 52100 0.03
Alger Management Ltd 35633 0.02
First Trust Portfolios L.P. 19101 0.01
DNB Asset Management AS 17425 0.01
Hennion & Walsh, Inc 400 0
Inspire Investing (CWM Advisors, LLC) 341 0
Peroni Portfolio Advisors, Inc 300 0

Похожие компании

Описание ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.